These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 31041007)
1. The price of shortening anti-hepatitis C virus therapy: Is this truly cost saving? Younossi ZM Clin Liver Dis (Hoboken); 2015 Nov; 6(5):126-128. PubMed ID: 31041007 [No Abstract] [Full Text] [Related]
2. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving. Chhatwal J; He T; Hur C; Lopez-Olivo MA Clin Gastroenterol Hepatol; 2017 Jun; 15(6):827-837.e8. PubMed ID: 27650326 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment. Goel A; Chen Q; Chhatwal J; Aggarwal R J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213 [TBL] [Abstract][Full Text] [Related]
4. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6. He T; Lopez-Olivo MA; Hur C; Chhatwal J Aliment Pharmacol Ther; 2017 Oct; 46(8):711-721. PubMed ID: 28836278 [TBL] [Abstract][Full Text] [Related]
5. Availability and affordability of priority life-saving medicines for under-five children in health facilities of Tigray region, northern Ethiopia. Abrha S; Tadesse E; Atey TM; Molla F; Melkam W; Masresha B; Gashaw S; Wondimu A BMC Pregnancy Childbirth; 2018 Nov; 18(1):464. PubMed ID: 30497441 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313 [TBL] [Abstract][Full Text] [Related]
7. [The significance and place of HBsAg neutralization test in the diagnosis and algorithm of hepatitis B infection]. Aytaç Ö; Toyran A; Aksoy A Mikrobiyol Bul; 2017 Apr; 51(2):136-144. PubMed ID: 28566077 [TBL] [Abstract][Full Text] [Related]
8. No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection. El Sherif O; Afhdal N; Curry M J Viral Hepat; 2017 Oct; 24(10):808-813. PubMed ID: 28581634 [TBL] [Abstract][Full Text] [Related]
9. Cost-benefit analysis of hepatitis-B vaccination. A computerized decision model for Spain. Jönsson B; Horisberger B; Bruguera M; Matter L Int J Technol Assess Health Care; 1991; 7(3):379-402. PubMed ID: 1834602 [TBL] [Abstract][Full Text] [Related]
10. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Hooman N; Rifai K; Hadem J; Vaske B; Philipp G; Priess A; Klempnauer J; Tillmann HL; Manns MP; Rosenau J Liver Transpl; 2008 Apr; 14(4):435-42. PubMed ID: 18383078 [TBL] [Abstract][Full Text] [Related]
11. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments. Dickson S; Reynolds I JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176 [TBL] [Abstract][Full Text] [Related]
12. A Guide to the Economics of Hepatitis C Virus Cure in 2017. Linas BP; Nolen S Infect Dis Clin North Am; 2018 Jun; 32(2):447-459. PubMed ID: 29778265 [TBL] [Abstract][Full Text] [Related]
13. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis. Krahn M; Detsky AS Med Decis Making; 1993; 13(1):4-20. PubMed ID: 8433635 [TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals. Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426 [TBL] [Abstract][Full Text] [Related]
15. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China]. Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456 [No Abstract] [Full Text] [Related]
16. Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. Gellad ZF; Muir AJ; McHutchison JG; Sievert W; Sharara AI; Brown KA; Flisiak R; Jacobson IM; Kershenobich D; Manns MP; Schulman KA; Reed SD Value Health; 2012; 15(6):876-86. PubMed ID: 22999138 [TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa. Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639 [TBL] [Abstract][Full Text] [Related]
19. Economic evaluations of hepatitis A vaccination in middle-income countries. Suwantika AA; Yegenoglu S; Riewpaiboon A; Tu HA; Postma MJ Expert Rev Vaccines; 2013 Dec; 12(12):1479-94. PubMed ID: 24168129 [TBL] [Abstract][Full Text] [Related]
20. Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation. Cenderello G; Artioli S; Viscoli C; Pasa A; Giacomini M; Giannini B; Dentone C; Nicolini LA; Cassola G; Di Biagio A Clinicoecon Outcomes Res; 2016; 8():15-21. PubMed ID: 26770065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]